sales@jinjingroup.com

  News Introduction

Vinpocetine(CAS 42971-09-5) injection treat Alzheimer's, different companies have the different marketing strategies

Date : 2016/10/18 10:35:24

According to PDB data, from 2005 to 2016 into the domestic samples of dementia hospital samples purchased a total of 15 varieties, these varieties are: 1 oxiracetam, 2 vinpocetine(CAS 42971-09-5), 3 brain protein hydrolyzate, 4 phosphocholine, 5 compounded piracetam, 13 compound piracetam, 13 compound piracetam, 13 compound piracetam, 9 aniracetam, 10 ripiracetam, + Brain protein hydrolyzate, 14 pyrithiol, 15 galanthamine. The leading five varieties of procurement amount of the trend shown in Figure 3, in which the fastest growth rate of oxiracetam from 2005 to 2015, 10 years of compound annual growth rate of 54% in 2013, the growth rate slowed down, the annual growth rate Less than 20%; 2015 growth rate of less than 10%.

Vinpocetine(CAS 42971-09-5) injection, for example, the bidding group will be greatly compressed, in order to bid, different manufacturers will be more intense price competition.

There is a difference in the structure of the Alzheimer's treatment (dementia treatment) at home and abroad, memantine (market share of 42%), rivastigmine (20%), donepezil (13%) as the main species, The domestic to oxacitam (51% market share), vinpocetine(CAS 42971-09-5) (19%), citicoline (10%) as the main species. The same species of different companies in the market performance of this shift, which may be the clinical efficacy of these drugs is not obvious, different companies have the different marketing strategies.